Even as Federal prosecutors linkurl:may be deciding;http://www.the-scientist.com/news/display/37502/ to focus their efforts on alleged misconduct by NIH researcher linkurl:Thomas Walsh;http://ccr.nci.nih.gov/Staff/Staff.asp?profileid=5598 , Walsh is apparently still not disclosing all of his potential conflicts of interest in his publications. Walsh -- who engaged in ''serious misconduct'' by accepting more than $100,000 in consulting fees from drug and biotech companies without disclosing the funding, according to an internal NIH report ?- is the lead author on a linkurl:study published online;http://www.journals.uchicago.edu/CID/journal/issues/v44n1/39344/39344.web.pdf on November 28 in Clinical Infectious Diseases of the treatment of invasive aspergillosis with posaconazole, a Schering-Plough drug. That study will appear in print in the journal's January 1, 2007 issue. What's noteworthy is that 21 of Walsh's 23 coauthors disclosed conflicts of various kinds, such as funding or fees from Schering-Plough or from Merck and Pfizer, who make drugs that compete with posaconazole. Walsh and Charles White reported no conflicts. I don't know...
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?